Abstract

Oral, quick response, and on demand, also known as a spontaneous oral treatment for erectile dysfunction, is highly needed by both patients and physicians. Vardenafil is selective (fewer side effects) and more effective in difficult-to-treat conditions than sildenafil. This study aims at fostering the dual objectives of using biomolecules such as artificial sweetening agents to solubilize and mask the bitterness of vardenafil loaded on biodegradable polymeric materials (PVA, MC, SA, and PVP K30) to fabricate oral, fast-dissolving films (vardenafil ODFs) in the mouth without the need for water to ingest the dosage form. Furthermore, coprecipitated-dispersed mixtures of vardenafil and three sweeteners (sorbitol, acesulfame K, and sucralose) were prepared and characterized using FTIR, DSC, and solubility studies. Moreover, eight different vardenafil ODFs were prepared using the solvent-casting method. Modified gustatory sensation test, in vitro disintegration, and release studies were performed. In addition, the optimized ODF (F8) was compared with the commercial film-coated tablets pharmacokinetically (relative bioavailability, onset, and duration of actions were estimated). The results indicated that the three sweetening agents had comparable solubilizing capacity. However, both sucralose- and acesulfame K-based ODFs have a more enhanced sweet and palatable taste than sorbitol-sweetened ODF. The SA- and PVP K30-based ODFs showed significantly faster disintegration times and release rates than MC. In conclusion, PVA has good film-forming properties, but a higher ratio of PVA adversely affected the disintegration and release characteristics. The % relative bioavailability for ODF was 126.5%, with a superior absorption rate constant (Ka) of 1.2-fold. The Cmax and estimated Tmax were compared to conventional film-coated tablets.

Highlights

  • Erectile dysfunction is among the most common health issues affecting men

  • Discussion primary use to enhance the organoleptic properties of vardenafil Oral dispersible films (ODFs)

  • Enhancement ofsoluble vardenafil was for three the poorly drugsolubility vardenafil in recorded addition to vardenafil:sorbitol, vardenafil:acesulfame

Read more

Summary

Introduction

Erectile dysfunction is among the most common health issues affecting men. Pharmaceutics 2022, 14, 517 of erectile dysfunction has been shifted dramatically to non-invasive oral therapy. Sildenafil (Viagra® 100 mg and 50 mg film-coated tablets) was the first PDEI member launched into the market in 1998 [3]. A few years later, vardenafil was approved for the oral treatment of erectile dysfunction in 2003. PDEI oral therapy has substantially succeeded in treating erectile dysfunction, being non-invasive and convenient for the patients. Delayed response, lack of spontaneity, and rapid sexual response have been reported with the film-coated tablets of vardenafil and sildenafil [4]. Both patients and clinicians demand fast and spontaneous responses to sexual intercourse [4]. Vardenafil is 5–10 times more potent and selective as a PDE inhibitor than sildenafil

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call